Drug    DrugBank | All Description Patterns💬 Info on mouse-over

No.	Drug (Description in trials)	DrugBank	KEGG DRUG	KEGG GENES	KEGG PATHWAY On map, Yellow: Drug target genes	Disease ID
1	150 mg double-blinded secukinumab	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 271 💬
2	150 mg open-label secukinumab	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 271 💬
3	300 mg double-blinded secukinumab	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 271 💬
4	Cosentyx	-	-	-	-	[3] 41, 269, 271 💬
5	Cosentyx®	-	-	-	-	[1] 269 💬
6	Secukinumab	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[7] 13, 37, 41, 46, 160, 269, 271 💬
7	Secukinumab (150 mg)	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 271 💬
8	Secukinumab (75 mg)	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 271 💬
9	Secukinumab (ain457)	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 46 💬
10	Secukinumab (ain457) 150 mg s.c.	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 271 💬
11	Secukinumab 150 mg (2 injections per dose	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 269 💬
12	Secukinumab 150 mg provided in 1.0 ml pre-filled syringes (pfss) for sc injection.	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 271 💬
13	Secukinumab 150 mg/1 ml solution for injection	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[2] 37, 271 💬
14	Secukinumab 150 milligram [cosentyx]	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 271 💬
15	Secukinumab 150mg	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 37 💬
16	Secukinumab 300 mg, s.c.	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 41 💬
17	Secukinumab 300mg	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 37 💬
18	Secukinumab 75 mg/0.5 ml solution for injection	Secukinumab	[1] D09967 💬	[1] IL17A 💬	[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation	[1] 271 💬